CS176291A3 - Pharmaceutical - Google Patents

Pharmaceutical Download PDF

Info

Publication number
CS176291A3
CS176291A3 CS911762A CS176291A CS176291A3 CS 176291 A3 CS176291 A3 CS 176291A3 CS 911762 A CS911762 A CS 911762A CS 176291 A CS176291 A CS 176291A CS 176291 A3 CS176291 A3 CS 176291A3
Authority
CS
Czechoslovakia
Prior art keywords
pharmaceutical composition
composition according
active ingredient
substituent
phenyl
Prior art date
Application number
CS911762A
Other languages
Czech (cs)
English (en)
Inventor
James Warren Winkelman
Blaik Phillip Halling
Debra Ann Witkowski
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of CS176291A3 publication Critical patent/CS176291A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CS911762A 1990-06-11 1991-06-10 Pharmaceutical CS176291A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53579490A 1990-06-11 1990-06-11

Publications (1)

Publication Number Publication Date
CS176291A3 true CS176291A3 (en) 1992-08-12

Family

ID=24135791

Family Applications (1)

Application Number Title Priority Date Filing Date
CS911762A CS176291A3 (en) 1990-06-11 1991-06-10 Pharmaceutical

Country Status (7)

Country Link
AU (1) AU8185491A (pt)
CS (1) CS176291A3 (pt)
IE (1) IE911971A1 (pt)
IL (1) IL98405A0 (pt)
PT (1) PT97937A (pt)
WO (1) WO1991019418A1 (pt)
ZA (1) ZA914435B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
US5767373A (en) 1994-06-16 1998-06-16 Novartis Finance Corporation Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US5939602A (en) * 1995-06-06 1999-08-17 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6023012A (en) * 1996-02-28 2000-02-08 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase
US6084155A (en) * 1995-06-06 2000-07-04 Novartis Ag Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
PL328617A1 (en) * 1996-02-28 1999-02-01 Novartis Ag Promotors of protoporphyrinogen oxidase genes residing in plants
CN103694243B (zh) * 2013-12-20 2015-09-09 中国农业大学 2-取代吡啶基-1,2,4-三唑并[1,2-a]哒嗪化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190371B (en) * 1980-12-18 1986-08-28 The Wellcome Foundation Ltd,Gb Process for producing ether-type compounds and pharmaceutical compositions containing them as active agents
CA1192545A (en) * 1982-02-16 1985-08-27 Glaxo Group Limited Heterocyclic derivatives as histamine h.sub.2- antagonists
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4820722A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazoles and their use as leukotriene antagonists
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione

Also Published As

Publication number Publication date
AU8185491A (en) 1992-01-07
IL98405A0 (en) 1992-07-15
PT97937A (pt) 1992-04-30
IE911971A1 (en) 1991-12-18
ZA914435B (en) 1992-03-25
WO1991019418A1 (en) 1991-12-26

Similar Documents

Publication Publication Date Title
KR930003116B1 (ko) 종양의 광역학적 치료용 조성물
US5407808A (en) Method and composition for photodynamic treatment and detection of tumors
Goldstein et al. Interaction of pergolide with central dopaminergic receptors.
Ajagbonna et al. Haematological and biochemical changes in rats given extract of Calotropis procera
AU648886B2 (en) Transdermal composition
US5298502A (en) Method and composition for photodynamic treatment and detection of tumors
TNSN98199A1 (fr) Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l&#39;indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant
Bevan et al. In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency
US4898878A (en) Antioxidant thiohistidine compounds
CS176291A3 (en) Pharmaceutical
Kondo et al. Coproporphyrin isomers in Dubin-Johnson syndrome
Beaven et al. Inhibition of histamine methylation in vivo by the dimaprit analog, SKF compound 91488
US4771130A (en) Target-entrapped drugs
RU2074719C1 (ru) Способ разрушения опухолевых клеток млекопитающих и фармацевтическая композиция для разрушения опухолевых клеток млекопитающих
FR2634380A1 (fr) Regulateur biologique, actif dans diverses pathologies
KR100785375B1 (ko) 중금속중독 예방을 위한 사료.
Conaway et al. Subchronic toxicity of benzyl selenocyanate and 1, 4-phenylenebis (methylene) selenocyanate in F344 rats
FR2459658A1 (fr) Procede de preparation d&#39;une composition pharmaceutique a base de methoxsalen administrable par voie orale
FR2642310A1 (fr) Association d&#39;un inhibiteur de la squalene synthetase et d&#39;un autre type d&#39;agent d&#39;abaissement de la cholesterolemie
LT3997B (en) Process for preparing protoporphyrins and use thereof
Nabih et al. Structure and activity in molluscicides II. Activity assay of catalase and peroxidase in snails
HRP930762A2 (en) Preparation and use of porphyrin
Austen et al. Historical and continuing perspectives on the biology of the leukotrienes
Bhatnagar et al. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
HERBERT results. A mixture of oxalacetic decarboxylase, malic de